We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00430547
First Posted: February 2, 2007
Last Update Posted: February 2, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborators:
University of Melbourne
National Health and Medical Research Council, Australia
Information provided by:
Barwon Health
February 1, 2007
February 2, 2007
February 2, 2007
August 2003
Not Provided
Onset or progression of ophthalmopathy following radio-active iodine therapy
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies
The purpose of this study is to determine whether radioactive iodine, as compared to anti-thyroid medications, is a risk factor for the development or progression of thyroid-associated ophthalmopathy in patients with hyperthyroidism due to Graves' disease. The other aim of this study is to determine the incidence of the various ophthalmopathy subtypes and the utility of orbital antibodies in the diagnosis, classification and monitoring of patients with thyroid-associated ophthalmopathy.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Graves' Ophthalmopathy
Drug: Carbimazole, radio-active iodine (I131)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
60
January 2006
Not Provided

Inclusion Criteria:

  • Graves' disease diagnosed in the last 3 months, regardless of the presence of ophthalmopathy

Exclusion Criteria:

  • Pre-existing eye disease: e.g. orbital surgery, orbital irradiation or significant loss of vision
  • Age < 18 years
  • Inability to consent to participation in the study
  • Pregnancy
  • History of radio-active iodine therapy
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Australia
 
 
NCT00430547
03/53
Not Provided
Not Provided
Not Provided
Not Provided
Barwon Health
  • University of Melbourne
  • National Health and Medical Research Council, Australia
Principal Investigator: Jack R Wall, BMBS, FRACP, PhD University of Sydney
Barwon Health
August 2003

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP